Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 17.54
XON's Cash to Debt is ranked lower than
55% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. XON: 17.54 )
Ranked among companies with meaningful Cash to Debt only.
XON' s 10-Year Cash to Debt Range
Min: 9.17  Med: 97.55 Max: N/A
Current: 17.54
Equity to Asset 0.78
XON's Equity to Asset is ranked higher than
62% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. XON: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
XON' s 10-Year Equity to Asset Range
Min: -2.12  Med: 0.71 Max: 0.8
Current: 0.78
-2.12
0.8
F-Score: 2
Z-Score: 17.06
M-Score: 4.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -142.16
XON's Operating margin (%) is ranked lower than
58% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. XON: -142.16 )
Ranked among companies with meaningful Operating margin (%) only.
XON' s 10-Year Operating margin (%) Range
Min: -1008.77  Med: -394.92 Max: -97.26
Current: -142.16
-1008.77
-97.26
Net-margin (%) -60.09
XON's Net-margin (%) is ranked higher than
52% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. XON: -60.09 )
Ranked among companies with meaningful Net-margin (%) only.
XON' s 10-Year Net-margin (%) Range
Min: -1043.69  Med: -379.24 Max: -113.75
Current: -60.09
-1043.69
-113.75
ROE (%) -13.54
XON's ROE (%) is ranked higher than
62% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. XON: -13.54 )
Ranked among companies with meaningful ROE (%) only.
XON' s 10-Year ROE (%) Range
Min: -172.6  Med: -97.19 Max: -21.78
Current: -13.54
-172.6
-21.78
ROA (%) -9.86
XON's ROA (%) is ranked higher than
64% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. XON: -9.86 )
Ranked among companies with meaningful ROA (%) only.
XON' s 10-Year ROA (%) Range
Min: -61.45  Med: -15.65 Max: -12.55
Current: -9.86
-61.45
-12.55
ROC (Joel Greenblatt) (%) -158.98
XON's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. XON: -158.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XON' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -872.72  Med: -243.33 Max: -230.87
Current: -158.98
-872.72
-230.87
» XON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

XON Guru Trades in Q2 2014

First Eagle Investment 661,564 sh (New)
Daniel Loeb 2,900,000 sh (-3.33%)
David Einhorn 375,000 sh (-72.81%)
» More
Q3 2014

XON Guru Trades in Q3 2014

First Eagle Investment 790,364 sh (+19.47%)
Daniel Loeb 2,900,000 sh (unchged)
David Einhorn 197,278 sh (-47.39%)
» More
Q4 2014

XON Guru Trades in Q4 2014

T Boone Pickens 10,000 sh (New)
Daniel Loeb 2,900,000 sh (unchged)
David Einhorn Sold Out
First Eagle Investment 789,864 sh (-0.06%)
» More
Q1 2015

XON Guru Trades in Q1 2015

Chase Coleman 300,000 sh (New)
First Eagle Investment 828,104 sh (+4.84%)
Daniel Loeb 2,700,000 sh (-6.90%)
Daniel Loeb 2,700,000 sh (-6.90%)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Intrexon Corp

Daniel Loeb Comments on Intrexon Corporation - Jan 22, 2014

Equity Position: Intrexon Corporation (XON) ("Intrexon") We initially invested in Intrexon in 2011 in a private round and have continued to accumulate shares since its IPO in August 2013. We believe that Intrexon is an innovation leader in synthetic biology with a unique value proposition and proven leadership team. Most attractive to us is Intrexon's potential to transform multiple industries, including the health, food, and energy markets. 

Synthetic biology is an emerging discipline that applies engineering design principles to biologic systems. Broadly speaking, synthetic biology is about the design, modification, and regulation of gene programs to produce a desired outcome, such as the production of a novel antibody from a cell culture, the optimization of a specific gene trait in crops, or the amplification of wild type natural gas metabolism into an industrially feasible process. Over the past 15 years, Intrexon has developed deep expertise in synthetic biology as well as the adjacent fields of process optimization and data analysis to create a unique technology platform that enables the iterative, directed improvement of experimental design. 

To leverage its technology with collaborators, Intrexon has developed a unique business model that centers on Exclusive Channel Collaborations (ECCs) with partners. In exchange for providing access to their technology, Intrexon receives cost reimbursement (thus mitigating the need to raise additional external funds) and significant downstream economics. Because Intrexon's technology is scalable, its capaci ty to sign ECCs across multiple industries is limited only by the ambition of its partners. Indeed, to date, Intrexon has already signed over 15 ECCs including, notably, with Johnson & Johnson. Over the course of 2014 and beyond, we anticipate that Intrexon will sign multiple ECCs, creating a broad pipeline of projects and diversifying away from specific product risk.

Intrexon is led by Chairman and CEO Randal J. Kirk, one of the most successful healthcare leaders of all time. Kirk founded and led New River Pharmaceuticals until its acquisition by Shire, and led Clinical Data through the successful development and approval of the anti-depressant Viibryd before selling the company to Forest. 

While his track record of value creation speaks for itself, we especially like that Kirk has personally invested significantly in Intrexon's success through Third Security , which owns nearly 2/3 of Intrexon's shares outstanding. While Intrexon's business model may seem foreign to the healthcare industry, it reminds us of an undisputed technology leader: Qualcomm. Qualcomm out-licenses its CDMA technology and in return receives significant economics from its partners upon commercialization; the explosive growth of the global wireless communication market and its dominant position has driven Qualcomm to a $125 billion market cap. W hile we aren't saying that Intrexon will become a $125 billion company overnight, we will note the following two points: (1) the manipulation of DNA and gene sequences to produce beneficial outcomes is a well-established paradigm; (2) the global health, food, and energy markets dwarf the wireless communication market in size

 

 

From Daniel Loeb (Trades, Portfolio)'s Third Point fourth quarter 2013 commentary.

Check out Daniel Loeb latest stock trades

Ratios

vs
industry
vs
history
P/B 8.26
XON's P/B is ranked lower than
69% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. XON: 8.26 )
Ranked among companies with meaningful P/B only.
XON' s 10-Year P/B Range
Min: 3.58  Med: 6.30 Max: 10.51
Current: 8.26
3.58
10.51
P/S 50.52
XON's P/S is ranked lower than
73% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. XON: 50.52 )
Ranked among companies with meaningful P/S only.
XON' s 10-Year P/S Range
Min: 5.94  Med: 36.61 Max: 67.47
Current: 50.52
5.94
67.47
EV-to-EBIT -81.99
XON's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. XON: -81.99 )
Ranked among companies with meaningful EV-to-EBIT only.
XON' s 10-Year EV-to-EBIT Range
Min: -57  Med: -31.10 Max: -16.4
Current: -81.99
-57
-16.4
Current Ratio 4.90
XON's Current Ratio is ranked higher than
53% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. XON: 4.90 )
Ranked among companies with meaningful Current Ratio only.
XON' s 10-Year Current Ratio Range
Min: 0.81  Med: 6.29 Max: 10.49
Current: 4.9
0.81
10.49
Quick Ratio 4.37
XON's Quick Ratio is ranked higher than
51% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. XON: 4.37 )
Ranked among companies with meaningful Quick Ratio only.
XON' s 10-Year Quick Ratio Range
Min: 0.81  Med: 6.02 Max: 10.49
Current: 4.37
0.81
10.49
Days Inventory 150.86
XON's Days Inventory is ranked lower than
63% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. XON: 150.86 )
Ranked among companies with meaningful Days Inventory only.
XON' s 10-Year Days Inventory Range
Min: 244.37  Med: 244.37 Max: 244.37
Current: 150.86
Days Sales Outstanding 55.91
XON's Days Sales Outstanding is ranked higher than
55% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. XON: 55.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
XON' s 10-Year Days Sales Outstanding Range
Min: 0.89  Med: 7.94 Max: 73.99
Current: 55.91
0.89
73.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2440.00
XON's Price/Net Cash is ranked lower than
100% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. XON: 2440.00 )
Ranked among companies with meaningful Price/Net Cash only.
XON' s 10-Year Price/Net Cash Range
Min: 21.96  Med: 29.80 Max: 2187.2
Current: 2440
21.96
2187.2
Price/Net Current Asset Value 88.73
XON's Price/Net Current Asset Value is ranked lower than
97% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. XON: 88.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
XON' s 10-Year Price/Net Current Asset Value Range
Min: 20.21  Med: 32.73 Max: 1791.4
Current: 88.73
20.21
1791.4
Price/Tangible Book 13.01
XON's Price/Tangible Book is ranked lower than
77% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. XON: 13.01 )
Ranked among companies with meaningful Price/Tangible Book only.
XON' s 10-Year Price/Tangible Book Range
Min: 6.9  Med: 8.19 Max: 12.23
Current: 13.01
6.9
12.23
Price/Median PS Value 1.40
XON's Price/Median PS Value is ranked lower than
58% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. XON: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
XON' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 1.01 Max: 1.75
Current: 1.4
0.2
1.75
Earnings Yield (Greenblatt) (%) -1.19
XON's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. XON: -1.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XON' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.6  Med: 0.00 Max: 0
Current: -1.19
-3.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:I5X.Germany,
Intrexon Corp was founded in 1998. The Company designs, builds and regulates gene programs and cellular systems to enable the development of new and improved products and processes across a variety of market sectors, including Health, Food, Energy and Environment.The Company operates in one segment. It uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company's revenues are derived in the United States of America and all of its assets are located in the United States of America. The Company is subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials and the health and safety of employees with respect to laboratory activities required for the development of products and technologies.
» More Articles for XON

Headlines

Articles On GuruFocus.com
Intrexon Corp is expanding his business Jun 25 2015 
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Other Websites
Juno Therapeutics, Kite Pharma, Eleven Bio Lead Monday's After-Hours Movers Jun 29 2015
Fibrocell Joins the Russell 2000(R) Index Jun 29 2015
Intrexon, Enanta Among Top Biotech New Issues Jun 24 2015
Soligenix Announces Collaboration with the National Organization for Rare Disorders and the... Jun 23 2015
INTREXON CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Jun 18 2015
INTREXON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Jun 17 2015
Intrexon Forms Multi-Year Collaboration with New Dedicated Fund Jun 15 2015
Intrexon Forms Multi-Year Collaboration with New Dedicated Fund Jun 15 2015
First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the... Jun 12 2015
Here’s why some investors think Ziopharm is poised for a $10B merger Jun 11 2015
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral... Jun 10 2015
June 10, 2015 - Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics... Jun 10 2015
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral... Jun 10 2015
Intrexon, Fibrocell Announce Positive Pre-Clinical Data - Analyst Blog Jun 09 2015
Coverage initiated on Intrexon by Wunderlich Jun 09 2015
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of... Jun 08 2015
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of... Jun 08 2015
Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares Jun 05 2015
INTREXON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 05 2015
Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares Jun 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK